Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eng Huat Tan

Showing results (71-80 of 108) with videos related to

Pageof 11
Sort By:
Scientific Reports|October 15, 2016
Lipidomic Profiling of Lung Pleural Effusion Identifies Unique Metabotype for EGFR Mutants in Non-Small Cell Lung CancerYing Swan Ho, Lian Yee Yip, Nurhidayah Basri, et al.
Journal of the National Cancer Institute|April 19, 2013
Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysisChee Khoon Lee, Chris Brown, Richard J Gralla, et al.
Human Genomics|July 17, 2023
Landscape of germline pathogenic variants in patients with dual primary breast and lung cancerNing-Yuan Lee, Melissa Hum, Sabna Zihara, et al.
Journal of Cancer Research and Clinical Oncology|February 21, 2019
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progressionMartin Schuler, Eng-Huat Tan, Kenneth O'Byrne, et al.
Translational Lung Cancer Research|May 17, 2023
Real world efficacy of osimertinib in second line/beyond in patients with metastatic EGFR+ non-small cell lung cancer and role of paired tumour-plasma T790M testing at tyrosine kinase inhibitor resistanceJun Ma, Sze Huey Tan, Daniel Xing Cheng Yin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 21, 2011
Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancerEng-Huat Tan, Glenwood D Goss, Ravi Salgia, et al.
Lung Cancer (Amsterdam, Netherlands)|May 18, 2019
Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancerKeunchil Park, Jaafar Bennouna, Michael Boyer, et al.
Clinical Lung Cancer|April 15, 2018
Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 TrialsYi-Long Wu, Lecia V Sequist, Eng-Huat Tan, et al.
International Journal of Radiation Oncology, Biology, Physics|June 11, 2018
Concurrent-Adjuvant Chemoradiation Therapy for Stage III-IVB Nasopharyngeal Carcinoma-Exploration for Achieving Optimal 10-Year Therapeutic RatioWai-Tong Ng, Stewart Y Tung, Victor Lee, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 26, 2010
A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinomaAnne W M Lee, Stewart Y Tung, Anthony T C Chan, et al.
Pageof 11

Showing results (71-80 of 108) with videos related to

Sort By:
Pageof 11
Scientific Reports|October 15, 2016
Lipidomic Profiling of Lung Pleural Effusion Identifies Unique Metabotype for EGFR Mutants in Non-Small Cell Lung CancerYing Swan Ho, Lian Yee Yip, Nurhidayah Basri, et al.
Journal of the National Cancer Institute|April 19, 2013
Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysisChee Khoon Lee, Chris Brown, Richard J Gralla, et al.
Human Genomics|July 17, 2023
Landscape of germline pathogenic variants in patients with dual primary breast and lung cancerNing-Yuan Lee, Melissa Hum, Sabna Zihara, et al.
Journal of Cancer Research and Clinical Oncology|February 21, 2019
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progressionMartin Schuler, Eng-Huat Tan, Kenneth O'Byrne, et al.
Translational Lung Cancer Research|May 17, 2023
Real world efficacy of osimertinib in second line/beyond in patients with metastatic EGFR+ non-small cell lung cancer and role of paired tumour-plasma T790M testing at tyrosine kinase inhibitor resistanceJun Ma, Sze Huey Tan, Daniel Xing Cheng Yin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 21, 2011
Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancerEng-Huat Tan, Glenwood D Goss, Ravi Salgia, et al.
Lung Cancer (Amsterdam, Netherlands)|May 18, 2019
Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancerKeunchil Park, Jaafar Bennouna, Michael Boyer, et al.
Clinical Lung Cancer|April 15, 2018
Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 TrialsYi-Long Wu, Lecia V Sequist, Eng-Huat Tan, et al.
International Journal of Radiation Oncology, Biology, Physics|June 11, 2018
Concurrent-Adjuvant Chemoradiation Therapy for Stage III-IVB Nasopharyngeal Carcinoma-Exploration for Achieving Optimal 10-Year Therapeutic RatioWai-Tong Ng, Stewart Y Tung, Victor Lee, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 26, 2010
A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinomaAnne W M Lee, Stewart Y Tung, Anthony T C Chan, et al.
Pageof 11